June 2009 Issue of MMM
MedEd Guide 2009
Steep competition for grants, onerous regulation and a politicized climate have led some providers to rethink involvement in continuing medical education. Marc Iskowitz reports
PI CME may be poised to become the predominant format
Once in a while, a CME program comes along that achieves off-the-charts responses. James Chase investigates why MPR Pillars of Care was such a hit
ACCME's upcoming firewall restrictions have led many firms to abandon CME for promotional med ed
Five key players look at what's in store for the future of med ed and how changes to the way it's regulated will impact the ...
HLS, part of CommonHealth, has excelled as a provider of scientific message-focused programming delivered by using dynamic innovative media options that address the modern pharmaceutical ...
Excerpta Medica Inc., an Elsevier business, is a global medical communications company headquartered in the US and The Netherlands.
Haymarket Medical Education (HME) is a medical communications company with more than 20 years of experience in producing top-quality continuing medical education/continuing education (CME/CE) programs.
MedscapeCME is an ACCME, ANCC, and ACPE accredited provider with a fully dedicated editorial staff that develops and publishes independent educational content on 33 specialty-focused ...
OptumHealth Education is a full-service, ACCME-accredited provider of continuing medical education dedicated to strengthening the ability of healthcare professionals to make accurate and credible decisions ...
Pri-Med is a trusted communication and education platform for science and medicine that is owned by M|C Communications LLC.
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.
Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.